KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 74 filers reported holding KINNATE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $32,392 | -88.3% | 23,138 | -74.7% | 0.00% | – |
Q2 2023 | $276,643 | +9.0% | 91,301 | +124.7% | 0.00% | – |
Q1 2023 | $253,901 | +84.8% | 40,624 | +80.4% | 0.00% | – |
Q4 2022 | $137,384 | -73.5% | 22,522 | -48.0% | 0.00% | – |
Q3 2022 | $518,000 | -25.3% | 43,312 | -21.2% | 0.00% | – |
Q2 2022 | $693,000 | +59.7% | 54,938 | +42.0% | 0.00% | – |
Q1 2022 | $434,000 | -31.2% | 38,691 | +8.7% | 0.00% | – |
Q4 2021 | $631,000 | -93.2% | 35,594 | -91.2% | 0.00% | -100.0% |
Q3 2021 | $9,273,000 | +357.7% | 402,875 | +362.8% | 0.00% | – |
Q2 2021 | $2,026,000 | – | 87,053 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |